Procter & Gamble Health Ltd (PGHL)
₹5,670.50
Mkt cap
₹9,413 Cr
P/E ratio
28.20
P/B
17.94
Div yield
2.73%
ROE
61.90%
ROCE
83.90%
EPS (TTM)
₹201.08
Book value
₹316
52W range
4,707–6,975
Sector
Healthcare
Price history
Previous close
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. [1]
NSE PGHLBSE 500126
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsNeutral
52-week range
−18.70% from high₹5,671
₹4,707+20.47% from low₹6,975
Current
₹5,670.50
Prev close
₹5,513.50
Day
+2.85%
Price performance
1D
+3.37%
1W
+13.65%
1M
+0.06%
3M
−12.34%
6M
+10.99%
1Y
−6.81%
YTD
−0.54%
Financials
Revenue, profit & margin
P/E ratio
28.2×
PGHL is 18% below the sector median of 34.4×
PGHL28.2×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 | |
| Expenses | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 | |
| Operating Profit | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 | |
| OPM % | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% | |
| Other Income | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 | |
| Profit before tax | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 | |
| Tax % | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% | |
| Net Profit | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 | |
| EPS in Rs | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
2 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.26% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | +1.26% |
| +1 day | −1.68% |
| +5 days | −2.24% |
| +15 days | −6.55% |
| +30 days | −9.30% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.82%Promoter
Promoters51.82%
FIIs6.43%0.10
DIIs12.63%0.19
Public29.13%0.28
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| P & G Health Ltd | ₹5,670.50 | 28.25 | 9,413 | 2.73% | 96 | +9.50% | 364 | +7.37% | 83.88% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts7
Credit ratings5
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Please find attached signed Certifiacte for confirming compliance under Regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended September 30, 2026.Board Meeting Intimation for Intimation Of Board Meeting 30 Sep - Board meeting on November 2, 2026 to consider unaudited Q2 and half-year results.Closure of Trading Window 25 Sep - Trading window closed from October 1, 2026 until 48 hours after Q2 FY27 results.Intimation Regarding Ease Of Doing Investment - Special Window For Transfer And Dematerialization 18 Sep - SEBI special window for re-lodgement of physical share transfer deeds extended till February 4, 2027.Re-Appointment Of Mr. S. Madhavan As Independent Director Of The Company. 4 Sep - Shareholders approved Mr. S. Madhavan’s five-year reappointment as Independent Director from November 15, 2026.